|  |  | HLAâ€
| APM loss ‡
| β2m loss ‡
|
|---|
RST N = 81 | MSS | + | 40 | 0 | 0 |
| Â | N = 48 (59,3%) | - | 8 (16,7%) | 3 (37,5%)* | 0 |
| Â | MSI-H | + | 13 | 0 | 0 |
| Â | N = 33 (41,7%) | - | 20 (60,6%) | 7 (35,0%)* | 1 (5,0%)* |
HNPCC N = 75 | MSI-H | + | 43 | 0 | 0 |
| Â | Â | - | 32 (42,7%) | 2 (6,3%)* | 15 (46,9%)* |
- * – The percentage of cases that lost APM or β2m expression is relative to the number of HLA negative cases of each subset
- †– HLA expression differs significantly between sporadic MSI-H and MSS tumors (p < 0.0001) and between HNPCC and sporadic MSS tumors (p < 0.005)
- ‡ – The association of HLA class I loss with that of β2m and of APM components differs significantly (p < 0.0001) between sporadic RST and HNPCC tumors.
